Exelixis, Inc. EX9.DE Stock
Exelixis, Inc. Price Chart
Exelixis, Inc. EX9.DE Financial and Trading Overview
| Exelixis, Inc. stock price | 21.09 EUR |
| Previous Close | 21.09 EUR |
| Open | 21.09 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 21.09 - 21.09 EUR |
| 52 Week Range | 14.02 - 22.01 EUR |
| Volume | 92 EUR |
| Avg. Volume | 75 EUR |
| Market Cap | 6.79B EUR |
| Beta (5Y Monthly) | 0.67676 |
| PE Ratio (TTM) | 23.175823 |
| EPS (TTM) | 0.91 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
EX9.DE Valuation Measures
| Enterprise Value | 5.74B EUR |
| Trailing P/E | 23.175823 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.0793076 |
| Price/Book (mrq) | 2.6825235 |
| Enterprise Value/Revenue | 3.451 |
| Enterprise Value/EBITDA | 33.712 |
Trading Information
Exelixis, Inc. Stock Price History
| Beta (5Y Monthly) | 0.67676 |
| 52-Week Change | 28.01% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 22.01 EUR |
| 52 Week Low | 14.02 EUR |
| 50-Day Moving Average | 19.88 EUR |
| 200-Day Moving Average | 18.16 EUR |
EX9.DE Share Statistics
| Avg. Volume (3 month) | 75 EUR |
| Avg. Daily Volume (10-Days) | 108 EUR |
| Shares Outstanding | 321.83M |
| Float | 294.13M |
| Short Ratio | N/A |
| % Held by Insiders | 2.41% |
| % Held by Institutions | 92.26% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 9.24% |
| Operating Margin (ttm) | 8.83% |
| Gross Margin | 96.45% |
| EBITDA Margin | 10.23% |
Management Effectiveness
| Return on Assets (ttm) | 3.17% |
| Return on Equity (ttm) | 6.34% |
Income Statement
| Revenue (ttm) | 1.66B EUR |
| Revenue Per Share (ttm) | 5.16 EUR |
| Quarterly Revenue Growth (yoy) | 14.79% |
| Gross Profit (ttm) | 1.55B EUR |
| EBITDA | 170.31M EUR |
| Net Income Avi to Common (ttm) | 153.74M EUR |
| Diluted EPS (ttm) | 0.91 |
| Quarterly Earnings Growth (yoy) | -41.60% |
Balance Sheet
| Total Cash (mrq) | 1.31B EUR |
| Total Cash Per Share (mrq) | 4.03 EUR |
| Total Debt (mrq) | 186.95M EUR |
| Total Debt/Equity (mrq) | 7.32 EUR |
| Current Ratio (mrq) | 4.999 |
| Book Value Per Share (mrq) | 7.862 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 299.3M EUR |
| Levered Free Cash Flow (ttm) | 135.46M EUR |
Profile of Exelixis, Inc.
| Country | Germany |
| State | CA |
| City | Alameda |
| Address | 1851 Harbor Bay Parkway |
| ZIP | 94502 |
| Phone | 650 837 7000 |
| Website | https://www.exelixis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1223 |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Q&A For Exelixis, Inc. Stock
What is a current EX9.DE stock price?
Exelixis, Inc. EX9.DE stock price today per share is 21.09 EUR.
How to purchase Exelixis, Inc. stock?
You can buy EX9.DE shares on the XETRA exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Exelixis, Inc.?
The stock symbol or ticker of Exelixis, Inc. is EX9.DE.
Which industry does the Exelixis, Inc. company belong to?
The Exelixis, Inc. industry is Biotechnology.
How many shares does Exelixis, Inc. have in circulation?
The max supply of Exelixis, Inc. shares is 321.83M.
What is Exelixis, Inc. Price to Earnings Ratio (PE Ratio)?
Exelixis, Inc. PE Ratio is 23.17582300 now.
What was Exelixis, Inc. earnings per share over the trailing 12 months (TTM)?
Exelixis, Inc. EPS is 0.91 EUR over the trailing 12 months.
Which sector does the Exelixis, Inc. company belong to?
The Exelixis, Inc. sector is Healthcare.